吉西他滨联合多西紫杉醇治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Gemcitabine and Docetaxel Combinations in Treatment on Aadvanced Non-small-cell Lung Cancer

作　　者：董海鹰[1] 陈公琰[1] 李晓莉[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院内一科,哈尔滨市150040

出　　处：《中国肿瘤临床》2006年第18期1029-1031,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察非铂类药物吉西他滨(健择)和多西紫杉醇(泰索帝)联合治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:43例NSCLC给予健择1000mg/m2,d1,d8,静脉滴注30min,泰索帝75mg/m2,d1,静脉滴注,28d为一个周期,至少治疗2个周期。结果:全组40例可评价疗效,无CR,PR14例,总有效率为35%(CR+PR),SD30%(12/40),PD32.5%(13/40),中位生存期为10个月,疾病进展时间为7.2个月;1年生存率及2年生存率分别为37.5%(15/40)和12.5%(5/40)。不良反应主要是骨髓抑制,其中Ⅲ～Ⅳ度白细胞下降有13例(32.5%),Ⅲ～Ⅳ度血小板下降有7例(17.5%);非血液学毒性表现为恶心及呕吐,Ⅰ～Ⅱ度有30例(75%),无Ⅲ～Ⅳ度恶心及呕吐;口腔粘膜炎有14例(35%),便秘有20例(50%),几乎所有患者均脱发。结论:吉西他滨和多西紫杉醇联合对于晚期NSCLC疗效较理想,不良反应较低,经过防治可以耐受,对于提高生活质量、延长生存期有意义,是可以替代铂类药物的有效方案。Objective： To observe the clinical and adverse effect of gemcitabine plus docetaxel, the non-platinum agents, in treatment on non-small cell lung cancer （NSCLC）. Methods： Gemcitabine （1000mg/m^2, dl, d8） plus docetaxel （75mg/m^2, iv drop, dl） were administered to 43 patients, Ⅳ drop 30min, with 28d a cycle and for 2 cycles of treatment at least. Results： Three patients discontinued because of treatment-related adverse effects, so the forty patients were estimated at last. The overall response rate was 35%. Median survival time and the median time for progression of disease （TTP） was 10 months and 7.2 months, and the 1-year and 2-year survival rate was 37.5% and 12.5%, respectively. The main adverse effect was myelo-suppression （〉 or =Grade Ⅲ） and leukopenia （32.5%）. No nausea and vomiting of grade Ⅲ/Ⅳ were found. Other toxicities were mild. All adverse effects were tolerated by sustaining therapy and allopathy. Conclusion： Gemcitabine plus docetaxel is an active and well-tolerated regimen and represents an option for treatment of the patients with advanced NSCLC. It will be of significance for enhancement of quality of life and extension of life span and can be used as an effective regimen to substitute the platinum drugs.

关 键 词：吉西他滨 多西紫杉醇 非小细胞肺癌 化学疗法 

分 类 号：R734.2[医药卫生—肿瘤]